Â鶹ѧÉú¾«Æ·°æ

Daniel A. Ermann
( out of 102 reviews )

Daniel A. Ermann, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

2D, Hematology
Salt Lake City
801-585-2626

  • Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 102 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 23, 2025
    HUNTSMAN CANCER CENTER

    Dr Ermann is very thorough, personable and knowledgeable. Great experience, highly recommend.

    March 11, 2025
    HUNTSMAN CANCER CENTER

    Dr. Ermann is extremely knowledgeable and is patient in explaining what he thinks is the best treatment for my cancer. I trust is judgement and skills.

    February 24, 2025
    HUNTSMAN CANCER CENTER

    Dr. Ermann is the very best. He's so knowledgeable, so kind,very patient and kind. I'm so lucky to be a patient of his. I wouldn't want any one else. Thank Dr. Ermann.

    February 22, 2025
    HUNTSMAN CANCER CENTER

    Dr. Ermann is a very knowledgeable and caring professional who treats you with respect and concern. Not too many physicians will call you directly with the results of the testing - he did several times.

    February 22, 2025
    HUNTSMAN CANCER CENTER

    Dr ermann always takes time to answer and explain things in a way we can understand

    February 13, 2025
    HUNTSMAN CANCER CENTER

    Dr. Ermann is great. Answered all my questions.

    January 20, 2025
    HUNTSMAN CANCER CENTER

    Presents himself in a very professional manner and is a good listener. Felt comfortable with him providing an initial evaluation of my condition and gave me clear understanding of what was to be done.

    January 09, 2025
    HUNTSMAN CANCER CENTER

    I have a high regard for Dr Ermann as a CLL specialist very knowledgeable.

    December 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Ermann is very thorough and answered all my many questions completely and made me feel completely at ease and informed about my newly diagnosed CLL. I would highly recommended him to anyone dealing with this type of cancer!

    See More Patient Comments

  • Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Administrative Chief Fellow
    Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Fellow
    Residency Internal Medicine - Creighton University School of Medicine Chief Resident
    Residency Internal Medicine - Creighton University School of Medicine Resident
    Professional Medical Medicine - St. George's University School of Medicine M.D.
    Undergraduate Major: Biology; Minor: Chemistry - University of Pittsburgh B.S.

    Selected Publications

    Journal Article

    1. Stephens DM, Stewart C, Avruch L, Coombs CC, Danilov A, Hill B, Shadman M, Gerrie A, Jensen CE, Hoffmann M, Winter A, Ermann DA, Barr PM, OBrien S, Koffman B, Byrd JC (2025). Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective. Clin Lymphoma Myeloma Leuk. ()
    2. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clin Lymphoma Myeloma Leuk. ()
    3. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann D (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. J Natl Compr Canc Netw, 23(3.5). ()
    4. Soumerai JD, Barrientos JC, Ahn IE, Coombs CC, Gladstone DE, Hoffmann MS, Kittai AS, Jacobs RW, Lipsky A, Patel K, Rhodes JM, Skarbnik AP, Thompson MC, Ermann DA, Reville PK, Shah HR, Brown JR, Stephens DM (2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Adv. ()
    5. Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M (2024). Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Blood Adv. ()
    6. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. ()
    7. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. ()
    8. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. ()
    9. Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA (2022). Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem, 3(3), 930-935. ()
    10. Ermann DA, Vardell VA, Kallam A, Silberstein PT, Armitage JO (2019). Academic Centers Compared With Nonacademic Centers for Patients With International Prognostic Index Risk-stratified Diffuse Large B-cell Lymphoma: A Survival Outcomes Analysis. Clin Lymphoma Myeloma Leuk, 20(4), e174-e183. ()
    11. Pierce TP, Ermann D, Scillia AJ, Festa A, Emami A, McInerney VK (2019). National Trends in Orthopaedic Surgery Resident Adult Case Logs. J Surg Educ, 76(3), 893-897. ()
    12. Vardell Noble V, Ermann DA, Griffin EK, Silberstein PT (2019). Primary Thyroid Lymphoma: An Analysis of the National Cancer Database. Cureus, 11(2), e4088. ()
    13. Ermann DA, Noble VV, Fazeel HM, Thomas B, Silberstein PT (2019). Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. Fed Pract, 36(Suppl 1), S30-S33. ()

    Commentary

    1. Ermann DA, and Kittai AS (2024). Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach. ASCO Daily News. ASCO Daily News.

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. ()
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. ()

    Abstract

    1. Steven M Bair, Mayur Narkhede, Zachary AK Frosch, Elise A Chong, Daniel A Ermann, Iris Isufi, Farrukh T Awan, Julio C Chavez, Grace N Bosma, and Diana Abbott (2023). Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy [Abstract].
    2. Sanjal H Desai, Nuttavut Sumransub, Rich Evans, Marcus P Watkins, Reem Karmali, MD, Gaurav Goyal, Mitchell E Hughes, Arushi Khurana, Francisco J Hernandez-Ilizaliturri, Joanna Zurko, Ayesha Hassan, Haris Hatic, Imran A Nizamuddin, Andrew M Evens, Andrea Carolina Anampa-Guzmn, Yi Lin, MD, Iris Isufi, Mehdi Hamadani, Saurabh A Rajguru, Naveena Lall, Aung M Tun, Brian T Hill, Deborah M Stephens, Paolo F Caimi, Daniel A Ermann, Brad S Kahl, Daniel J Landsburg, and Grzegorz S Nowakowski (2023). Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy [Abstract].

  • News & Podcasts

    Huntsman Cancer Institute News